Annual Report 2022

The road ahead

Read more about our strategy and business idea


Investor relations

Dicot develops a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.

In August 2023, Dicot started its clinical phase 1 study of the drug candidate LIB-01 with the primary objective of evaluating the safety profile in humans. The first study participants were dosed in early September, and the final clinical visits were made in April 2024. Further development is intended to be carried out under own auspices up to and including clinical phase 2a and then together with major pharmaceutical companies to introduce LIB-01 to the world market.

Dicot's shares are listed on Spotlight Stock Market and the company has approximately 5,500 shareholders.

The global market for treating sexual dysfunctions is annually worth more than 50 billion SEK as the underlying causes increase and the proportion of elderly increases

Today's potency drugs were launched over twenty years ago and have limitations

Up to 35% of men with erection problems do not respond to current treatments. LIB-01 works differently and opens up the possibility of being helped

Existing drugs have a duration of action of maximum 36 hours. According to studies, LIB-01 can have an effect lasting at least seven days

Sexual medicine experts states that there is a great need for new potency drugs

In Sweden only one out of four seeks medical help for erectile dysfunction due to the condition's stigma

IR contact

Elin Trampe CEO

Telephone: +46 72 502 1010